@BALANCE_VIEW In addition, Sinopharm vaccine phase III trial was conducted in UAE which is home to over 200 nationalities, allowing for robust research across multiple ethnicities and increasing its feasibility for global application. Hence, there is no need to provide any additional data to support the applicability in the Malaysian population.
In certain countries like China, if the data suggests ethnic inconsistencies in effectiveness and safety, and racial sensitivity analyses do not demonstrate safety and efficacy for Chinese patients, it will only be considered “partially acceptable,” in which case a bridging study with Chinese subjects must be conducted. Hence, this is why Pfizer was required to conduct a bridging study in China despite already conducting phase III clinical trials in USA.
11. DOCUMENTS FOR INSPECTION The SPAs will be made available for inspection at the registered office of KANGER at No. 2- 1, Jalan Sri Hartamas 8, Sri Hartamas, 50480 Kuala Lumpur, Wilayah Persekutuan (KL), during business hours from Monday to Friday (except public holidays) for a period of three (3) months from the date of this announcement. This announcement is dated 24 August 2020.
@BALANCE_VIEW No, as i mentioned above, Sinopharm vaccine phase III trial was conducted in UAE which is home to over 200 nationalities, allowing for robust research across multiple ethnicities and increasing its feasibility for global application. Hence, there is no need to provide any additional data to support the applicability of the vaccine in the Malaysian population.
kanger glove plant by right be ready in 1st Qtr 2021. hiw come no news one. land approved. no build structure kah. how to hit production schedule lah. correct?
@BALANCE_VIEW NPRA also accepts WHO prequalification (ie. approval) of vaccines. WHO prequalification is internationally recognized and is on par with approval from stringent regulatory authorities from NPRA reference countries such as USA FDA and EMA. Other reference countries include Canada, Japan, Australia, Switzerland, Sweden, France and UK.
@BALANCE_VIEW Occasionally, NPRA may also approve drugs/ vaccines from non reference countries on a case to case basis if it meets all the requirements.
wow. kanger collecting rental 11mil lah. why no one promote this news. 11mil will be very good future income lah. correct?
Kanger, which has completed the development of AutoCity and Kyriad Hotel, located within the Ganzhou Economic and Technological Development Zone in Ganzhou city, China said the land acquisition was expected to be completed within 45 days from the agreement with CHL.
In March, Kanger had secured 10-year lease agreements for AutoCity and Kyriad Hotel.
The initial rental income per year for the two buildings collectively is RM11.1 million, and is subject to scheduled rent increases.
Kanger invests RM77mil on glove factory By Sharen Kaur August 14, 2020 @ 11:02pm
Kanger invests RM77mil on glove factory KUALA LUMPUR: Kanger International Bhd, which makes bamboo wood products, is setting up a glove manufacturing plant in Ijok, Selangor for about RM77 million.
Kanger told Bursa Malaysia today it has incorporated a wholly-owned subsidiary, Kanger Glove Manufacturing Sdn Bhd, which will acquire around five acres in Ijok for RM6.8 million.
Kanger Glove would spend RM70 million to build the plant and install up to eight production lines to produce medical, surgical and/or nitrile gloves, Kanger said in a filing with Bursa.
The stock closed two sen lower at 26.5 sen today. Some 43.6 million shares changed hands.
Kanger said it had on August 13, entered into heads of agreement with Dubai-based Constellation Holdings Ltd (CHL), which would acquire a 49 per cent equity in Kanger Glove for RM49,000.
Kanger announced on Tuesday it had received a formal expression of interest letter (EOI), dated August 9, from CHL to set up the medical examination gloves operations in Malaysia.
The EOI expresses CHL's intention to collaborate with KIB through several options, which include direct equity participation by forming a joint-venture entity, and/or indirect equity holding in the glove manufacturing operations via investment into Kanger through a private placement exercise.
Kanger said a substantial proportion of the total output of the production would be sold to CHL.
CHL is the appointed procurement agency for personal protective equipment, medical equipment and supplies for the Ministry of Health and Prevention of the United Arab Emirates, and other countries in Middle East.
The remaining output would be reserved to develop other market channels in Asia and Europe, it said.
"All investment cost as well as the profit and loss of Kanger Glove shall be borne and/or distributed in accordance to the equities of the respective party in the company.
"CHL has the right to allocate part of its 49 per cent equity in Kangar Glove to other parties or investors it deems appropriate, subject to KIB's prior agreement on each party," Kanger said.
@UlarSawa Problem is there was no further update ever since that news came out in August. I wonder what’s the current status. Anyone contacted Kanger to find out ?
Kura2 said dont hope too much on vaccine, she told to wait until Q1 2021 to move on when bamboo flooring started the manufactuting, now plz q and wait at 0.145 again
can exclude vaccine also no problem lah. wait for glove news to come. schedule Q1 2021 production. must inform KYY about kanger plant so he can count howmuch kanger should worth lah. correct?
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
UlarSawa
35,552 posts
Posted by UlarSawa > 2020-12-08 16:28 | Report Abuse
anyone know what is kanger glove status?